Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020

SELL
$1.41 - $4.25 $416,903 - $1.26 Million
-295,676 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$1.25 - $2.02 $369,595 - $597,265
295,676 New
295,676 $438,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track 22 Nw, LP Portfolio

Follow 22 Nw, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 22 Nw, LP, based on Form 13F filings with the SEC.

News

Stay updated on 22 Nw, LP with notifications on news.